John Kilhefner

John Kilhefner

Senior Managing Editor, Lango Franchise

John Kilhefner is Senior Managing Editor of the Luke Lango franchise, which includes Hypergrowth Investing, Innovation Investor, Crypto Investor Network, and more.
Kilhefner has contributed to media such as Benzinga, The Hill, Tip Ranks, Unwinnable, The Arcade Review, Five Out of Ten magazine, and ZAM. He has appeared in U.S. News and World Report, Kotaku, USA Today, and Game Developer.
He now runs his own creative agency focused on tech and cybersecurity, called Skellator, LLC.
Learn more here

Recent Articles

Here’s Why Sarepta Therapeutics Inc Is Up 80% Today (SRPT)

By John Kilhefner, Senior Managing Editor, Lango Franchise

Sarepta Therapeutics Inc (SRPT) won approval for its Duchenne muscular dystrophy drug today, sending the biotech up more than 80%.

Infoblox Inc (BLOX) Pops on $1.6B Vista Equity Buyout

By John Kilhefner, Senior Managing Editor, Lango Franchise

Inloblox Inc (NYSE:BLOX) is returning to the private market in a deal by Vista Equity Partners that values BLOX stock at $1.6 billion.

3 Dependable Dividend Stocks to Buy for Shaky Times

By John Kilhefner, Senior Managing Editor, Lango Franchise

These three dependable dividend stocks boast strong underlying businesses and relentless dividend growth. They'll survive a rate hike easily -- if the Fed even delivers one.

VimpelCom Ltd (ADR) (VIP) Forfeits Gains on Secondary Offering

By John Kilhefner, Senior Managing Editor, Lango Franchise

VIP stock is being taken to the woodshed on intense volume after pricing a secondary offering of VimpelCom shares.

Novavax, Inc. (NVAX) Loses Almost Everything on Resolve Failure

By John Kilhefner, Senior Managing Editor, Lango Franchise

Novavax, Inc. (NASDAQ:NVAX) dropped like a stone amid disappointing trial data of its RSV vaccine. Can it bounce back?

Load More